STOCK TITAN

GE HealthCare names new president and CEO, China

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags

GE HealthCare (Nasdaq: GEHC) announced a leadership transition in its China operations. Yihao Zhang, current president and CEO of China, will retire effective July 1, 2025. Will Song, a Johnson & Johnson veteran of over 20 years, will take over the position, joining on April 1, 2025.

Under Zhang's leadership since 2019, GE HealthCare achieved significant growth in China, including doubled innovation investment within five years and expanded manufacturing presence across Beijing, Wuxi, Tianjin, Shanghai, with new sites in Chengdu and Shenzhen. Zhang established a clear blueprint for regional growth through localization and innovation strategies.

Song joins from Johnson & Johnson, where he served as global senior vice president and China chairman. He holds leadership positions in various industry associations and brings extensive experience in the Chinese healthcare market. Both executives will work together to ensure a smooth transition in this strategically important region.

GE HealthCare (Nasdaq: GEHC) ha annunciato un cambiamento nella leadership delle sue operazioni in Cina. Yihao Zhang, attuale presidente e CEO della Cina, andrà in pensione a partire dal 1 luglio 2025. Will Song, un veterano di Johnson & Johnson con oltre 20 anni di esperienza, assumerà la posizione, entrando in carica il 1 aprile 2025.

Sotto la guida di Zhang dal 2019, GE HealthCare ha raggiunto una significativa crescita in Cina, inclusi raddoppi degli investimenti in innovazione in cinque anni e un'espansione della presenza produttiva a Pechino, Wuxi, Tianjin e Shanghai, con nuovi siti a Chengdu e Shenzhen. Zhang ha stabilito un chiaro piano per la crescita regionale attraverso strategie di localizzazione e innovazione.

Song proviene da Johnson & Johnson, dove ha ricoperto il ruolo di vicepresidente senior globale e presidente per la Cina. Ricopre posizioni di leadership in varie associazioni di settore e porta con sé una vasta esperienza nel mercato sanitario cinese. Entrambi i dirigenti lavoreranno insieme per garantire una transizione fluida in questa regione strategicamente importante.

GE HealthCare (Nasdaq: GEHC) anunció una transición en el liderazgo de sus operaciones en China. Yihao Zhang, actual presidente y CEO de China, se retirará a partir del 1 de julio de 2025. Will Song, un veterano de Johnson & Johnson con más de 20 años de experiencia, asumirá el cargo, comenzando el 1 de abril de 2025.

Bajo el liderazgo de Zhang desde 2019, GE HealthCare logró un crecimiento significativo en China, incluyendo la duplicación de la inversión en innovación en cinco años y la expansión de la presencia manufacturera en Beijing, Wuxi, Tianjin y Shanghái, con nuevos sitios en Chengdu y Shenzhen. Zhang estableció un claro plan para el crecimiento regional a través de estrategias de localización e innovación.

Song se une a la compañía proveniente de Johnson & Johnson, donde se desempeñó como vicepresidente senior global y presidente de China. Ocupa posiciones de liderazgo en varias asociaciones de la industria y aporta una amplia experiencia en el mercado de la salud en China. Ambos ejecutivos trabajarán juntos para asegurar una transición fluida en esta región estratégicamente importante.

GE HealthCare (Nasdaq: GEHC)는 중국 운영의 리더십 전환을 발표했습니다. Yihao Zhang은 현재 중국의 회장 겸 CEO로, 2025년 7월 1일부로 은퇴할 예정입니다. Will Song은 Johnson & Johnson에서 20년 이상의 경력을 가진 베테랑으로, 2025년 4월 1일에 이직하여 직책을 맡게 됩니다.

2019년부터 Zhang의 리더십 아래 GE HealthCare는 중국에서 상당한 성장을 이루었으며, 5년 내에 혁신 투자액을 두 배로 늘리고 베이징, 우시, 톈진, 상하이에 제조 시설을 확장했으며, 청두와 선전에도 새로운 사이트를 개설했습니다. Zhang은 현지화 및 혁신 전략을 통해 지역 성장에 대한 명확한 청사진을 수립했습니다.

Song은 Johnson & Johnson에서 글로벌 수석 부사장 및 중국 회장으로 재직하였으며, 여러 산업 협회에서 리더십 직책을 맡고 있으며, 중국 의료 시장에 대한 폭넓은 경험을 가지고 있습니다. 두 임원은 이 전략적으로 중요한 지역에서 원활한 전환을 보장하기 위해 함께 협력할 것입니다.

GE HealthCare (Nasdaq: GEHC) a annoncé une transition de leadership dans ses opérations en Chine. Yihao Zhang, président et PDG actuel de la Chine, prendra sa retraite à compter du 1er juillet 2025. Will Song, un vétéran de Johnson & Johnson avec plus de 20 ans d'expérience, prendra la relève, rejoignant l'entreprise le 1er avril 2025.

Sous la direction de Zhang depuis 2019, GE HealthCare a réalisé une croissance significative en Chine, y compris un doublement des investissements en innovation en cinq ans et une expansion de sa présence manufacturière à Pékin, Wuxi, Tianjin et Shanghai, avec de nouveaux sites à Chengdu et Shenzhen. Zhang a établi un plan clair pour la croissance régionale grâce à des stratégies de localisation et d'innovation.

Song rejoint l'entreprise en provenance de Johnson & Johnson, où il a occupé le poste de vice-président senior mondial et président pour la Chine. Il occupe des postes de direction dans diverses associations professionnelles et apporte une vaste expérience du marché de la santé en Chine. Les deux dirigeants travailleront ensemble pour garantir une transition fluide dans cette région stratégiquement importante.

GE HealthCare (Nasdaq: GEHC) hat einen Führungswechsel in seinen China-Operationen angekündigt. Yihao Zhang, derzeit Präsident und CEO von China, wird zum 1. Juli 2025 in den Ruhestand treten. Will Song, ein Veteran von Johnson & Johnson mit über 20 Jahren Erfahrung, wird die Position übernehmen und am 1. April 2025 beginnen.

Unter Zhangs Führung seit 2019 hat GE HealthCare in China erhebliches Wachstum erzielt, einschließlich einer Verdopplung der Innovationsinvestitionen innerhalb von fünf Jahren und einer Erweiterung der Produktionspräsenz in Peking, Wuxi, Tianjin und Shanghai, mit neuen Standorten in Chengdu und Shenzhen. Zhang hat einen klaren Plan für das regionale Wachstum durch Lokalisierungs- und Innovationsstrategien etabliert.

Song kommt von Johnson & Johnson, wo er als globaler Senior Vice President und Vorsitzender von China tätig war. Er hat Führungspositionen in verschiedenen Branchenverbänden inne und bringt umfangreiche Erfahrung im chinesischen Gesundheitsmarkt mit. Beide Führungskräfte werden zusammenarbeiten, um einen reibungslosen Übergang in dieser strategisch wichtigen Region zu gewährleisten.

Positive
  • Expanded manufacturing footprint across 6 Chinese cities
  • Doubled innovation investment in China within 5 years
  • Secured experienced successor with 20+ years industry expertise
  • Planned 3-month transition period ensures business continuity
Negative
  • Loss of successful regional CEO who drove significant growth since 2019

Yihao Zhang to retire from GE HealthCare, hands over leadership position to long-time Johnson & Johnson executive, Will Song, a highly knowledgeable and respected leader with a proven track record and decades of industry experience

CHICAGO--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC), a leading global healthcare solutions provider, today announced that Yihao Zhang, president and CEO, China, will retire from the company effective July 1, 2025. Will Song, a Johnson & Johnson veteran for over 20 years, has been named GE HealthCare’s new president and CEO, China, and will join the company on April 1, 2025, ahead of leading the region starting July 1 following Yihao’s departure.

Yihao’s planned retirement allowed GE HealthCare to purposefully identify and prepare a qualified successor in Will, an exceptional leader with a strong track-record and the right skillsets to help deliver the company’s local strategy.

Since joining GE HealthCare in 2019, Yihao has been responsible for GE HealthCare’s strategic development and operations in China, driving the company’s long-term growth in the market. He has redefined the company’s localization, innovation and partnership strategy in China, establishing a clear blueprint for long-term growth in the region. His efforts in developing and promoting industry-leading localization have been critical in transforming the industry and helping the company navigate in the highly evolving, policy-driven and competitive market. He also doubled innovation investment within five years and expanded the company’s manufacturing footprint in Beijing, Wuxi, Tianjin and Shanghai and built two new manufacturing sites in Chengdu and Shenzhen.

“Yihao has proven himself to be a humble, energetic, people-focused leader who embraced our company culture, strategy and purpose. He has made an indelible mark on our colleagues and the industry,” said Peter Arduini, president and CEO, GE HealthCare. “I want to personally thank Yihao for his leadership and contributions through the years, and for positioning GE HealthCare as a leading innovator in China. I wish him a healthy and happy retirement. Looking ahead, I am confident that Will’s stellar reputation and in-depth knowledge of the China market, along with his robust relationships with key stakeholders and deep understanding of our customer base, will help enhance our position in China and move the region forward to effectively deliver on the future of healthcare.”

Will joins GE HealthCare from Johnson & Johnson, where he served as global senior vice president and China chairman. He led the China Presidents’ Council to advance Johnson & Johnson’s journey of innovation in China across MedTech and Innovative Medicine businesses. He joined Johnson & Johnson in 2003 and held various global positions with increasing responsibilities.

Well respected in the China market, over the past decade, Will has served as vice chairman of the China Association of Medical Devices Industry, vice president of the China Association of Enterprises with Foreign Investment, and vice chairman, Shanghai Enterprises Directors Association. He has been recognized with multiple external honors for his accomplishments, impact on the healthcare industry and broader economic development. He holds a bachelor’s degree from Peking University, an MBA from the Wharton School of the University of Pennsylvania, and a Ph.D. in Molecular Biology and Biochemistry from the University of Massachusetts.

Will is going to be based in Shanghai, China. Yihao and Will are working closely over the next several months to get immersed in the business, which is strategically important to the company’s growth strategy, and enable a deliberate and effective transition period.

About GE HealthCare Technologies Inc.

GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient’s journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.

GE HealthCare is proud to be among 2025 Fortune World’s Most Admired Companies™.

Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.

GE HealthCare Media Contact:

Jennifer Fox

414-530-3027

Jennifer.r.fox@gehealthcare.com

Lu Zhong

86-1810 113 1180

LuYin.Zhong@gehealthcare.com

Source: GE HealthCare Technologies Inc.

FAQ

When will Will Song take over as GE HealthCare's (GEHC) new China CEO?

Will Song will join GEHC on April 1, 2025, and officially assume the role of president and CEO, China on July 1, 2025.

What are the key achievements of Yihao Zhang during his tenure at GEHC China?

Zhang doubled innovation investment in 5 years and expanded manufacturing across Beijing, Wuxi, Tianjin, Shanghai, plus new sites in Chengdu and Shenzhen.

What is Will Song's background before joining GE HealthCare (GEHC)?

Song was Johnson & Johnson's global senior vice president and China chairman, with over 20 years of experience at the company.

How is GEHC ensuring a smooth leadership transition in China?

Zhang and Song will work together for several months before the July 2025 transition to ensure business continuity and effective knowledge transfer.

Ge Healthcare Technologies Inc

NASDAQ:GEHC

GEHC Rankings

GEHC Latest News

GEHC Stock Data

40.88B
455.35M
3.09%
84.02%
2.79%
Health Information Services
X-ray Apparatus & Tubes & Related Irradiation Apparatus
Link
United States
CHICAGO